AIDS critic seeks vote on Gilead's 'predatory' pricing
This article was originally published in Scrip
Executive Summary
With its lobbying efforts on the price of Gilead Sciences' new four-drug HIV combo Stribild apparently having a limited effect, frequent Gilead Sciences critic the AIDS Healthcare Foundation (AHF) is now sponsoring a local ballot initiative in San Francisco that could force local, state and federal governments to negotiate lower prices.